Vaccines Against Leishmaniasis

  • Awanish Kumar
Chapter
First Online:
Part of the SpringerBriefs in Immunology book series (BRIEFSIMMUN, volume 3)

Abstract

The development of a vaccine against leishmaniasis is a long term goal in both human and veterinary medicine. In the past decade, various subunit and DNA antigens have been identified as potential vaccine candidates in experimental animals but none have so far been approved for human use. To date there is no vaccine available against VL in routine use anywhere in the world. However, there is consensus that in the long term, vaccines ought to become a major tool in the control of this group of diseases. Unfortunately, the development of vaccines has been hampered by significant antigenic diversity and the fact that the parasites have a digenetic life cycle. Although a great number of antigens have been tested for protection against the cutaneous disease with in vitro cell or mouse models, no effective vaccine against human kala-azar is yet available. Though, the solid immunity observed following cure of kala-azar has suggested that the vaccination to prevent leishmaniasis is within the reach of conventional immunization methods, only few reports in literature deal with vaccines viz., FML, FML-QuilA Saponin against canine VL (Santos et al. 2002). Immune mechanisms involved in VL and various vaccines candidates evaluated in experimental models for VL has been extensively reviewed by Modabber (1995), Handman (2001), Scott (2003), Ravindran and Ali (2004), Goto and Lindoso (2004), Nyame et al. (2004), Kaye et al. (2004), Wilson et al. (2005), Garg and Dube (2006).

Keywords

Vaccine Candidate Cutaneous Leishmaniasis Delayed Type Hypersensitivity Response Potential Vaccine Candidate Meglumine Antimoniate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Bunn-Moreno MM, Madeira ED, Miller K, Menezes JA, Campos-Neto A (1985) Hypergammaglobulinaemia in Leishmania donovani infected hamsters: possible association with a polyclonal activator of B cells and with suppression of T cell function. Clin Exp Immunol 59:427–434PubMedGoogle Scholar
  2. Garg R, Dube A (2006) Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 123:439–454PubMedGoogle Scholar
  3. Ghose AC, Haldar JP, Pal SC, Mishra BP, Mishra KK (1980) Serological investigations on Indian kala-azar. Clin Exp Immunol 40:318–326PubMedGoogle Scholar
  4. Ghosh MK, Nandy A, Addy M, Maitra TK, Ghose AC (1995) Subpopulations of T lymphocytes in the peripheral blood, dermal lesions and lymph nodes of post kala-azar dermal leishmaniasis patients. Scand J Immunol 41:11–17PubMedCrossRefGoogle Scholar
  5. Goto H, Lindoso JA (2004) Immunity and immunosuppression in experimental visceral leishmaniasis. Braz J Med Biol Res 37:615–623PubMedCrossRefGoogle Scholar
  6. Handman E (1997) Leishmania vaccines: old and new. Parasitol Today 13:236–238PubMedCrossRefGoogle Scholar
  7. Handman E (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14:229–243PubMedCrossRefGoogle Scholar
  8. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP (1995) Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 63:4261–4267PubMedGoogle Scholar
  9. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, Stager S, Zubairi S, Engwerda CR (2004) The immunopathology of experimental visceral leishmaniasis. Immunol Rev 201:239–253PubMedCrossRefGoogle Scholar
  10. Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, Kharazmi A, Theander TG (1993) Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61:1069–1073PubMedGoogle Scholar
  11. Melby PC, Chandrasekar B, Zhao W, Coe JE (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166:1912–1920PubMedGoogle Scholar
  12. Modabber F (1995) Vaccines against leishmaniasis. Ann Trop Med Parasitol 89(Suppl 1):83–88PubMedGoogle Scholar
  13. Probst P, Skeiky YA, Steeves M, Gervassi A, Grabstein KH, Reed SG (1997) A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-alpha production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur J Immunol 27:2634–2642PubMedCrossRefGoogle Scholar
  14. Rezai HR, Ardehali SM, Amirhakimi G, Kharazmi A (1978) Immunological features of kala-azar. Am J Trop Med Hyg 27:1079–1083PubMedGoogle Scholar
  15. Santos WR, de Lima VM, de Souza EP, Bernardo RR, Palatnik M, Palatnik de Sousa CB (2002) Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21:30–43PubMedCrossRefGoogle Scholar
  16. Scott P (2003) Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol Res 27:489–498PubMedCrossRefGoogle Scholar
  17. Suffia I, Ferrua B, Stien X, Mograbi B, Marty P, Rousseau D, Fragaki K, Kubar J (2000) A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. Infect Immun 68:630–636PubMedCrossRefGoogle Scholar
  18. Yan S, Li F, Ding K, Sun H (2003) Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione. J Biol Inorg Chem 8:689–697PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Awanish Kumar
    • 1
  1. 1.School of Life SciencesJawaharlal UniversityNew DelhiIndia

Personalised recommendations